1017 related articles for article (PubMed ID: 25409858)
1. Adherence and persistence to urate-lowering therapies in the Irish setting.
McGowan B; Bennett K; Silke C; Whelan B
Clin Rheumatol; 2016 Mar; 35(3):715-21. PubMed ID: 25409858
[TBL] [Abstract][Full Text] [Related]
2. Estimation of adherence to urate-lowering therapy in people living with gout using Australia's Pharmaceutical Benefits Scheme and patient-reported dosing.
Schulz M; Coleshill MJ; Day RO; Wright DFB; Brett J; Briggs NE; Aung E
Br J Clin Pharmacol; 2024 May; 90(5):1322-1332. PubMed ID: 38382554
[TBL] [Abstract][Full Text] [Related]
3. Comparison of persistence rates between allopurinol and febuxostat as first-line urate-lowering therapy in patients with gout: an 8-year retrospective cohort study.
Kim A; Kim Y; Kim GT; Ahn E; So MW; Lee SG
Clin Rheumatol; 2020 Dec; 39(12):3769-3776. PubMed ID: 32458236
[TBL] [Abstract][Full Text] [Related]
4. Achieving serum urate goal: a comparative effectiveness study between allopurinol and febuxostat.
Hatoum H; Khanna D; Lin SJ; Akhras KS; Shiozawa A; Khanna P
Postgrad Med; 2014 Mar; 126(2):65-75. PubMed ID: 24685969
[TBL] [Abstract][Full Text] [Related]
5. Cost Comparison of Urate-Lowering Therapies in Patients with Gout and Moderate-to-Severe Chronic Kidney Disease.
Mitri G; Wittbrodt ET; Turpin RS; Tidwell BA; Schulman KL
J Manag Care Spec Pharm; 2016 Apr; 22(4):326-36. PubMed ID: 27023686
[TBL] [Abstract][Full Text] [Related]
6. A retrospective analysis of medication prescription records for determining the levels of compliance and persistence to urate-lowering therapy for the treatment of gout and hyperuricemia in The Netherlands.
Janssen CA; Oude Voshaar MAH; Vonkeman HE; Krol M; van de Laar MAFJ
Clin Rheumatol; 2018 Aug; 37(8):2291-2296. PubMed ID: 29721712
[TBL] [Abstract][Full Text] [Related]
7. Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.
Chohan S; Becker MA; MacDonald PA; Chefo S; Jackson RL
Arthritis Care Res (Hoboken); 2012 Feb; 64(2):256-61. PubMed ID: 22052584
[TBL] [Abstract][Full Text] [Related]
8. Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort.
Singh JA; Akhras KS; Shiozawa A
Arthritis Res Ther; 2015 May; 17(1):120. PubMed ID: 25963969
[TBL] [Abstract][Full Text] [Related]
9. Impact of noncompliance with urate-lowering drug on serum urate and gout-related healthcare costs: administrative claims analysis.
Halpern R; Mody RR; Fuldeore MJ; Patel PA; Mikuls TR
Curr Med Res Opin; 2009 Jul; 25(7):1711-9. PubMed ID: 19485724
[TBL] [Abstract][Full Text] [Related]
10. Persistence with urate-lowering therapy in Australia: A longitudinal analysis of allopurinol prescriptions.
Coleshill MJ; Day RO; Tam K; Kouhkamari M; Caillet V; Aung E; Kannangara DRW; Cronin P; Rodgers A; Stocker SL
Br J Clin Pharmacol; 2022 Nov; 88(11):4894-4901. PubMed ID: 35675118
[TBL] [Abstract][Full Text] [Related]
11. Achieving serum urate targets in gout: an audit in a gout-oriented rheumatology practice.
Corbett EJM; Pentony P; McGill NW
Int J Rheum Dis; 2017 Jul; 20(7):894-897. PubMed ID: 28205336
[TBL] [Abstract][Full Text] [Related]
12. Medication adherence among gout patients initiated allopurinol: a retrospective cohort study in the Clinical Practice Research Datalink (CPRD).
Scheepers LEJM; Burden AM; Arts ICW; Spaetgens B; Souverein P; de Vries F; Boonen A
Rheumatology (Oxford); 2018 Sep; 57(9):1641-1650. PubMed ID: 29893941
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular effects of urate-lowering therapies in patients with chronic gout: a systematic review and meta-analysis.
Zhang T; Pope JE
Rheumatology (Oxford); 2017 Jul; 56(7):1144-1153. PubMed ID: 28379501
[TBL] [Abstract][Full Text] [Related]
14. Achievement of the target serum urate level among patients with gout treated with allopurinol or febuxostat in an arthritis clinic in the Philippines.
Quilisadio JEC; Salido EO; Penserga EG
Mod Rheumatol; 2021 May; 31(3):755-761. PubMed ID: 32701037
[TBL] [Abstract][Full Text] [Related]
15. Modifiable factors associated with allopurinol adherence and outcomes among patients with gout in an integrated healthcare system.
Rashid N; Coburn BW; Wu YL; Cheetham TC; Curtis JR; Saag KG; Mikuls TR
J Rheumatol; 2015 Mar; 42(3):504-12. PubMed ID: 25512479
[TBL] [Abstract][Full Text] [Related]
16. Impact of Non-Adherence and Flare Resolution on the Cost-Effectiveness of Treatments for Gout: Application of a Linked Pharmacometric/Pharmacoeconomic Model.
Hill-McManus D; Marshall S; Soto E; Lane S; Hughes D
Value Health; 2018 Dec; 21(12):1373-1381. PubMed ID: 30502780
[TBL] [Abstract][Full Text] [Related]
17. Analysis of appropriate duration of colchicine prophylaxis to maximize the persistence of xanthine oxidase inhibitors as the first-line urate-lowering therapy in patients with gout using the Korean Health Insurance Review and Assessment Service database.
So MW; Kim AR; Lee SG
Int J Rheum Dis; 2023 Sep; 26(9):1770-1778. PubMed ID: 37431263
[TBL] [Abstract][Full Text] [Related]
18. The Budget Impact of Increased Use of Febuxostat in the Management of Gout: A US Health Plan Managed Care Pharmacy and Medical Costs Perspective.
Smolen LJ; Gahn JC; Mitri G; Shiozawa A
Clin Ther; 2016 Jul; 38(7):1710-25. PubMed ID: 27269247
[TBL] [Abstract][Full Text] [Related]
19. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout.
Becker MA; Schumacher HR; MacDonald PA; Lloyd E; Lademacher C
J Rheumatol; 2009 Jun; 36(6):1273-82. PubMed ID: 19286847
[TBL] [Abstract][Full Text] [Related]
20. Adherence with urate-lowering therapies for the treatment of gout.
Harrold LR; Andrade SE; Briesacher BA; Raebel MA; Fouayzi H; Yood RA; Ockene IS
Arthritis Res Ther; 2009; 11(2):R46. PubMed ID: 19327147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
